Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the Netherlands / NCT05359887
Active, not recruiting Not applicable

PET-study on the Role of the Reward System in Weight Loss After Bariatric Surgery

NCT05359887 · tracked via the Priya Life Science Netherlands tracker
Sponsor
University Medical Center Groningen
Phase
Not applicable
Started
2022-12-01
Last updated
2026-04-29

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

standardized liquid mixed meal Nutridrink®

standardized liquid mixed meal Nutridrink®: Administration of food in controlled situation

Study summary

Bariatric surgery (BS) is currently the most effective treatment in severe obesity. However, a considerable percentage of patients undergoing BS fail to lose sufficient weight or regain weight after initial weight loss during long-term follow-up, which may be attributed to personality traits and pathological eating behaviour. Previous positron emission tomography (PET) studies have shown reduced dopamine D2 receptor availability in obese patients and upregulation of this availability following successful BS in the brain's reward system. Dopamine D2 receptor availability in patients with unsuccessful BS has not been investigated to date.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Bariatric surgery 24-36 months prior to the study * Adult (over 18y old) * Mentally capable to understand the consequences of the procedure and make his or her own choice without coercion * Able to undergo PET and MRI, according to the investigator's assessment * Native speaking * Able to participate in follow-up * Written informed consent Exclusion Criteria: * Presence of a DSM-IV axis 1 disorder * The use of drugs that bind to dopamine D2/3 receptors, including various classes of antipsychotics and antidepressants * History of stroke, brain tumor, Parkinson's Disease or dementia * History of head trauma with loss of consciousness * Alcohol or substance abuse in the last 6 months * Alcohol consumption 24h prior to PET scanning * Smoking or other forms of nicotine intake 12 hours prior to PET scanning * Use of anorectic drugs in the last 6 months * Current pregnancy * Medication for Diabetes Mellitus * Claustrophobia * The presence of implanted metal objects of the type which may concentrate radiofrequency fields or cause tissue damage from twisting in a magnetic field (such as certain implanted devices, shrapnel, ocular metal shavings) * Patients with a bodyweight \> 200kg will be excluded to ensure the maximum load of the camera bed of the PET-scanner (227 kg) is not exceeded.

Primary outcome measure(s)

  • Change in [11C]-raclopride binding potential in the brain's reward system between study groups before and after a food challenge. — -50 minutes (before start of PET scanning), 0 minutes (during PET break, before mixed meal), 30 minutes (after second phase of PET-scanning)
    Pre- and post-eating changes in dopamine D2 receptor availability as indexed by the \[11C\]-raclopride binding potential in the brain's reward system between subjects who underwent successful vs unsuccessful bariatric surgery

Trial sites (1)

FacilityCityRegionStatus
MCL Leeuwarden Netherlands

More University Medical Center Groningen trials in the Netherlands

Asylumseekers Experiencing Paranoid Delusions: A Virtual Reality Study Recruiting
PD-L1 PET-imaging During CAR T-cell Therapy Active, not recruiting
Long-term Outcomes After Prolonged Dual Hypothermic Oxygenated Machine Perfusion of Donor Livers (DHOPEPROLONG) Recruiting
Investigating Cardiovascular Adverse Events Related to Cancer Treatment Active, not recruiting
Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer Recruiting

Other trials for the same condition

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight Recruiting
Butyrate-enriched Triglyceride and Diabetes Prevention Recruiting
A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants Active, not recruiting
Plant-based Protein-rich Weight Loss Intervention in 55+ Adults With Obesity Recruiting
A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05359887 on ClinicalTrials.gov ↗ ← All trials in the Netherlands